Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from ZYUS Life Sciences ( (TSE:ZYUS) ) is now available.
ZYUS Life Sciences has completed the first tranche of its non-brokered private placement, issuing 370,000 units at $0.67 per unit for gross proceeds of $247,900. The proceeds will be used for general corporate and working capital purposes. The offering has received conditional approval from the TSX Venture Exchange and is subject to final acceptance. The units were issued under exemptions from prospectus requirements and are subject to a hold period expiring in October 2025.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company focused on developing and commercializing novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to securing intellectual property protection and obtaining regulatory approval for non-opioid-based pharmaceutical solutions, aiming to transform patients’ lives.
Average Trading Volume: 19,020
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$45.2M
For an in-depth examination of ZYUS stock, go to TipRanks’ Overview page.